Colorectal Cancer Drugs Market Report 2026

Colorectal Cancer Drugs Market Overview

• Colorectal Cancer Drugs market size has reached to $21.72 billion in 2025 • Expected to grow to $28.57 billion in 2030 at a compound annual growth rate (CAGR) of 5.8% • Growth Driver: Rising Demand For Personalized Medicines Drives Growth In Colorectal Cancer Drugs Market • Market Trend: FDA Approval Of Lonsurf (Trifluridine/Tipiracil) For Metastatic Colorectal Cancer Treatment • North America was the largest region in 2025 and Middle East is the fastest growing region.

What Is Covered Under Colorectal Cancer Drugs Market?

Colorectal cancer (CRC) or bowel cancer, is a type of cancer affecting the large intestine and the rectum. Depending on where they begin, they are also known as colon tumors or rectal cancer. The main types of colorectal cancer drugs are vascular endothelial growth factor (VEGF) inhibitors, epidermal growth factor receptor (EGFR) inhibitors, and programmed cell death protein 1/PD1 ligand 1 (PD1/PDL1) inhibitors, BRAF or MEK inhibitors, tyrosine kinase (TKI) inhibitors, and immunomodulators. Vascular endothelial growth factors (VEGF) are drugs that block VEGF and VEGFR activity. The various classes of drugs include immunotherapy, chemotherapy, and others that are distributed by hospitals pharmacies, retail pharmacies, and others.

What Is The Colorectal Cancer Drugs Market Growth Forecast?

The colorectal cancer drugs market size is expected to see strong growth in the next few years. It will grow to $28.57 billion in 2030 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to emergence of immunotherapy and targeted therapies, integration of ai in drug development, growth in precision medicine adoption, expansion of oncology research funding, rise in combination treatment protocols. Major trends in the forecast period include personalized cancer therapies, immunotherapy advancements, targeted molecular treatments, early detection & screening technologies, combination therapy approaches.

Global Colorectal Cancer Drugs Market Segmentation

1) By Type: Vascular Endothelial Growth Factor (VEGF) Inhibitors, Epidermal Growth Factor Receptor (EGFR) Inhibitors, Programmed Cell Death Protein 1 Or PD1 Ligand 1 (PD1 Or PDL1) Inhibitors, BRAF Or MEK Inhibitors, Tyrosine Kinase (TKI) Inhibitors, Immunomodulators 2) By Class: Immunotherapy, Chemotherapy, Other Classes 3) By Distribution Channels: Hospitals Pharmacies, Retail Pharmacies, Other Distribution Channels Subsegments: 1) By Vascular Endothelial Growth Factor (VEGF) Inhibitors: Bevacizumab, Ramucirumab, Other VEGF Inhibitors 2) By Epidermal Growth Factor Receptor (EGFR) Inhibitors: Cetuximab, Panitumumab, Other EGFR Inhibitors 3) By Programmed Cell Death Protein 1 Or PD1 Ligand 1 (PD1 Or PDL1) Inhibitors: Pembrolizumab, Nivolumab, Other PD1 Or PDL1 Inhibitors 4) By BRAF Or MEK Inhibitors: Vemurafenib, Encorafenib, Trametinib, Other BRAF Or MEK Inhibitors 5) By Tyrosine Kinase (TKI) Inhibitors: Regorafenib, Sorafenib, Other TKI Inhibitors 6) By Immunomodulators: Checkpoint Inhibitors, Other Immunomodulating Agents

What Is The Driver Of The Colorectal Cancer Drugs Market?

The increasing demand for personalized medicines is expected tom propel the growth of the colorectal cancer drugs market going forward. Personalized medicine, also known as precision medicine, is an approach to medical treatment and healthcare that takes into account individual variations in patients' genes, environments, and lifestyles. Personalized medicine is transforming the approach to CRC treatment, offering more individualized and effective care for patients. It is likely to continue driving the growth of the CRC drug market as research and drug development efforts become more tailored to specific genetic and molecular profiles. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the FDA approved 16 new personalized therapies for patients with rare diseases, a significant increase from the six approved in 2022. Therefore, the increasing demand for personalized medicine is driving the growth of the colorectal cancer drugs industry.

Key Players In The Global Colorectal Cancer Drugs Market

Major companies operating in the colorectal cancer drugs market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Amgen Inc., Servier Laboratories, Eisai Co. Ltd., Taiho Pharmaceutical Co. Ltd., Taiho Oncology Inc., Daiichi Sankyo Company Limited, Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services Inc., Spectrum Pharmaceuticals Inc., Exelixis Inc., Seattle Genetics Inc., Incyte Corporation, Clovis Oncology Inc., Karyopharm Therapeutics Inc.

Global Colorectal Cancer Drugs Market Trends and Insights

Major companies operating in the colorectal cancer drugs market are receiving FDA approvals for new drugs such as LONSURF (trifluridine/tipiracil) to increase their profitability in the market. LONSURF (trifluridine/tipiracil) is an oral medication that is only available by prescription and is used to treat specific cancers, such as colon, rectal, and stomach cancer that has spread to other regions of the body. For instance, in August 2023, Taiho Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company announced that Food and Drug Administration has approved LONSURF (trifluridine/tipiracil) combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (mCRC). In comparison to LONSURF alone, the combination of LONSURF with bevacizumab significantly increased both overall survival (OS) and progression-free survival (PFS). With a hazard ratio of 0.61 (95% CI: 0.49, 0.77, 1-sided p0.001), the median OS was 10.8 months in the LONSURF + bevacizumab arm and 7.5 months in the LONSURF arm.

What Are Latest Mergers And Acquisitions In The Colorectal Cancer Drugs Market?

In October 2023, The Bristol-Myers Squibb Company, a US-based pharmaceutical company acquired Mirati Therapeutics Inc for a deal amount of $5.8 Billion. The acquisition was made to add KRAZATI, a significant lung cancer drug, to Bristol Myers Squibb's commercial portfolio in order to improve and diversify the company's oncology portfolio. With the purchase, Mirati's therapies will be able to help more people, quicker, and will be able to fulfil the company's mission of uncovering the science that lies behind the promise of a life free from cancer. Mirati Therapeutics Inc is a US-based biotech company.

Regional Insights

North America was the largest region in the colorectal cancer drugs market in 2025. The Middle East is expected to be the fastest-growing region in the global colorectal cancer drugs market share during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Colorectal Cancer Drugs Market?

The colorectal cancer drugs market consists of sales of avastin, bevacizumab, and camptosar. Values in the colorectal cancer drugs market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Colorectal Cancer Drugs Market Report 2026?

The colorectal cancer drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the colorectal cancer drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.